免疫治疗时代背景下放疗在晚期食管癌中的应用进展
作者简介:
王澜: 主任医师，教授，医学博士，博士研究生导师，河北医科大学第四医院胸部放疗二科主任。中国临床肿瘤学会（CSCO）肿瘤放射治疗专家委员会委员，中国医疗保健国际交流促进会放射治疗学分会委员，河北省医学会放射肿瘤学分会第六届委员会候任主委，河北省临床肿瘤学会肿瘤放射治疗专家委员会候任主委，中华医学会放射肿瘤治疗学分会委员会第十届青年学组委员，中国抗癌协会肿瘤放射治疗专业委员会第三届青委，河北省抗癌协会青年理事会常务青年理事，河北省抗癌协会肿瘤放射治疗专业委员会常务委员。主要致力于胸部恶性肿瘤放射治疗的临床与基础研究，发表论文70余篇，SCI 20余篇，获河北省科技进步二等奖三项，医学进步一等奖一项。《中国肿瘤临床》特约审稿专家，《医学参考报放射肿瘤治疗学》专刊第三届编委会编委
。
Progress of Research on Radiotherapy for Advanced Esophageal Cancer in the Era of Immunotherapy
-
摘要:
食管癌确诊时中晚期患者居多，一旦疾病进展至晚期阶段，预后极差，既往传统方案化疗的患者中位总生存期不足一年。免疫检查点抑制剂治疗为食管癌患者带来新的契机，改变了既往治疗格局，目前化疗联合免疫治疗（PD-1抑制剂）已成为晚期食管癌的标准一线治疗，即便如此，晚期患者的中位总生存期也仅能达到12.4~17.2个月，仍不足以满足临床需求。在系统性治疗基础上联合局部治疗，寻求新的综合治疗模式是提高晚期食管癌疗效的重要研究方向。本文现就放疗在晚期食管癌中的研究进展和前景予以综述。
Abstract:Esophageal cancer is predominantly diagnosed at a locally advanced or distant metastasis stage in patients. Once the disease progresses to the advanced stage, its prognosis is poor, and the median overall survival time of patients receiving traditional chemotherapy is less than one year. Treatment with immune checkpoint inhibitors has provided new opportunities to patients with esophageal cancer and changed the previous treatment pattern. Chemotherapy combined with immunotherapy (PD-1 inhibitor) has become the standard first-line treatment for advanced esophageal cancer. However, chemotherapy combined with immunotherapy have been reported a median overall survival time of only 12.4-17.2 months for patients. Such a survival time remains insufficient to meet clinical needs. Combining systemic treatment with local treatment and seeking new comprehensive treatment models are important research directions for improving efficacy. This article reviews the research progress and prospects of radiotherapy in the treatment of advanced esophageal cancer.
-
Key words:
- Advanced esophageal cancer /
- Immunotherapy /
- Radiotherapy
-
Competing interests: The author declares that she has no competing interests.利益冲突声明：所有作者均声明不存在利益冲突。
-
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] Arnold M, Abnet CC, Neale RE, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer[J]. Gastroenterology, 2020, 159(1): 335-349. e15.
[3] Kojima T, Shah MA, Muro K, et al. Randomized Phase Ⅲ KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. doi: 10.1200/JCO.20.01888
[4] Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842. doi: 10.1016/S1470-2045(20)30110-8
[5] Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2019, 17(7): 855-883. doi: 10.6004/jnccn.2019.0033
[6] Liu Y, Ren Z, Yuan L, et al. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer[J]. Am J Cancer Res, 2016, 6(10): 2345-2350.
[7] Hironaka S, Tsubosa Y, Mizusawa J, et al. Phase Ⅰ/Ⅱ trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807)[J]. Cancer Sci, 2014, 105(9): 1189-1195. doi: 10.1111/cas.12486
[8] Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(11): 1506-1517. doi: 10.1016/S1470-2045(19)30626-6
[9] Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. doi: 10.1016/S0140-6736(21)01234-4
[10] Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. doi: 10.1016/S0140-6736(21)00797-2
[11] Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial[J]. JAMA, 2021, 326(10): 916-925. doi: 10.1001/jama.2021.12836
[12] Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288. e3.
[13] Xu J, Jiang H, Pan Y, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial[J]. JAMA, 2023, 330(21): 2064-2074. doi: 10.1001/jama.2023.19918
[14] Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial[J]. Nat Med, 2023, 29(2): 473-482. doi: 10.1038/s41591-022-02179-2
[15] Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2023, 24(5): 483-495. doi: 10.1016/S1470-2045(23)00108-0
[16] Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021, 144: 232-241. doi: 10.1016/j.ejca.2020.11.039
[17] Jiang N, Zhang J, Guo Z, et al. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial[J]. J Immunother Cancer, 2024, 12(1): e008229. doi: 10.1136/jitc-2023-008229
[18] Chen R, Liu Q, Li Q, et al. A phase Ⅱ clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)[J]. EClinicalMedicine, 2023, 62: 102118. doi: 10.1016/j.eclinm.2023.102118
[19] Hingorani M, Dixit S, Johnson M, et al. Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer[J]. Cancer Res Treat, 2015, 47(4): 706-717. doi: 10.4143/crt.2014.174
[20] 中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2023年版)[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20. [Chinese Medical Doctor Association Radiation Oncologist Branch, Society of Radiation Oncology, Chinese Medical Association, Chinese Anti-Cancer Association tumor radiation therapy professional committee. Chinese Guidelines for Radiation Therapy of Esophageal Cancer (2023 edition)[J]. Guo Ji Zhong Liu Xue Za Zhi, 2024, 51(1): 1-20.] Chinese Medical Doctor Association Radiation Oncologist Branch, Society of Radiation Oncology, Chinese Medical Association, Chinese Anti-Cancer Association tumor radiation therapy professional committee. Chinese Guidelines for Radiation Therapy of Esophageal Cancer (2023 edition)[J]. Guo Ji Zhong Liu Xue Za Zhi, 2024, 51(1): 1-20.
[21] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
[22] Jamel S, Tukanova K, Markar S. Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review[J]. World J Gastrointest Oncol, 2019, 11(9): 741-749. doi: 10.4251/wjgo.v11.i9.741
[23] Chen Y, Cheng X, Song H, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases[J]. J Thorac Dis, 2019, 11(4): 1536-1545. doi: 10.21037/jtd.2019.03.10
[24] Liu Q, Zhu Z, Chen Y, et al. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3): 707-715. doi: 10.1016/j.ijrobp.2020.05.003
[25] Schizas D, Mylonas KS, Kapsampelis P, et al. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data[J]. Interact Cardiovasc Thorac Surg, 2020, 31(3): 299-304. doi: 10.1093/icvts/ivaa116
[26] Kroese TE, van Laarhoven HWM, Nilsson M, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis[J]. Eur J Cancer, 2022, 166: 254-269. doi: 10.1016/j.ejca.2022.02.018
[27] Liu Q, Chen J, Lin Y, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2024, 9(1): 45-55. doi: 10.1016/S2468-1253(23)00316-3
[28] Duan Y, Qin W, Yang L, et al. Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer[J]. Cancer Manag Res, 2023, 15: 55-65. doi: 10.2147/CMAR.S391529
[29] Zhao W, Ke S, Cai X, et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase Ⅱ trial[J]. Radiother Oncol, 2023, 184: 109679. doi: 10.1016/j.radonc.2023.109679
[30] Wu X, Li Y, Zhang K, et al. Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study[J]. Clin Transl Radiat Oncol, 2022, 38: 130-137.
[31] Wang C, Wang C, Jin L, et al. Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study[J]. Biomed Res Int, 2022, 2022: 7331687.
计量
- 文章访问数: 2687
- HTML全文浏览量: 4506
- PDF下载量: 1768
下载:
